Search Results

CNS Pharmaceuticals, Inc. today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the Virtual Investor Lunch Break: The CNSP Opportunity event on Tuesday, April 23, 2024 at 12:00 PM ET.

CNS Pharmaceuticals, Inc. announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at the LSX World Congress 2024 on Monday, April 29, 2024 at 4:15 PM in London, England.

CNS Pharmaceuticals, Inc. today reported its financial results for the first quarter 2024 ended March 31, 2024.

CNS Pharmaceuticals, Inc. today announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners on May 21, 2024 at 1:40 PM ET.

CNS Pharmaceuticals, Inc. today announced a 1-for-50 reverse split of its common stock, effective at 4:01 PM ET on June 4, 2024.

CNS Pharmaceuticals, Inc. announced that John Climaco, Chief Executive Officer of CNS Pharmaceuticals will present at two upcoming investor conferences being held in New York City in April.

CNS Pharmaceuticals, Inc. announced it has entered into securities purchase agreements with health-care focused institutional investors for the purchase and sale of 366,000 shares of common stock in a registered direct offering and warrants to purchase up to 366,000 shares of common stock in a concurrent private placement at a combined purchase price of $3.75 per share.

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (“CNS” or the “Company”) today reported its financial results for the full year ended December 31, 2023 and outlined recent corporate and clinical development highlights.